Ziagen

Generic Name: Ziagen

What is Ziagen?

Very rarely cases of erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported where abacavir hypersensitivity could not be ruled out. In such cases medicinal products containing abacavir should be permanently discontinued.

Many of the adverse reactions have not been treatment limiting. Metabolism and nutrition disordersCommon: anorexiaVery rare: lactic acidosis Nervous system disordersCommon: nausea, vomiting, diarrhoea Rare: pancreatitis Skin and subcutaneous tissue disordersCommon: rash without systemic symptoms Very rare: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis General disorders and administration site conditionsCommon: fever, lethargy, fatigue Description of Selected Adverse Reactions Abacavir hypersensitivity reactionsThe signs and symptoms of this HSR are listed below.

These have been identified either from clinical studies or post marketing surveillance. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise. Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours.

This recurrence of the HSR is usually more severe than on initial presentation, and may include life-threatening hypotension and death. Metabolic parametersWeight and levels of blood lipids and glucose may increase during antiretroviral therapy see section 4.

OsteonecrosisCases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown see section 4.

Changes in laboratory chemistries In controlled clinical studies laboratory abnormalities related to Ziagen treatment were uncommon, with no differences in incidence observed between Ziagen treated patients and the control arms.

Instruct patients that if they miss a dose of ZIAGEN, to take it as soon as they remember. Instruct patients to read the Medication Guide before starting ZIAGEN and to re-read it each time the prescription is renewed. Instruct patients to inform their physician or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.

A list of these symptoms is on the Warning Card your pharmacist gives you. If your healthcare provider tells you that you can take ZIAGEN again, start taking it when you are around medical help or people who can call a healthcare provider if you need one. ZIAGEN is a prescription HIV-1 Human Immunodeficiency Virus type 1 medicine used with other antiretroviral medicines to treat HIV-1 infection.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome AIDS. This may reduce your risk of death or getting infections that can happen when your immune system is weak opportunistic infections. ZIAGEN does not cure HIV-1 infection or AIDS. You must keep taking HIV-1 medicines to control HIV-1 infection and decrease HIV-related illnesses. What should I tell my healthcare provider before taking ZIAGEN.

How should I take Ziagen?

See Also: ZIAGEN ORAL SOLUTION Pharmacological Class: Nucleoside analogue reverse transcriptase inhibitor. Note: Register pregnant patients exposed to abacavir by calling 800 258-4263.

All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. It is used with other medicines to treat HIV. This medicine is not a cure for HIV.

What should I avoid while taking Ziagen?

Over time, as new copies of HIV are made in the body, the virus changes its structure. These changes are called mutations and can cause HIV to resist the effects of anti-HIV drugs, which means those drugs will no longer work for you.

Combining abacavir with at least two other anti-HIV drugs delays the development of drug resistance. To reduce the risk of developing drug resistance, all anti-HIV drugs should be taken every day exactly as prescribed and directed. If doses are delayed, missed, or not taken as prescribed, levels of abacavir in the blood may fall too low. If this happens, resistant virus can develop.

If you find you are having problems taking your medications as directed, speak to your doctor and nurse about this. They can find ways to help you.

Ziagen side effects

Because your medicine helps to control your condition, but does not cure it, you will need to take the tablets every day. Do not stop taking ZIAGEN tablets or change the dose without first talking to your doctor. If you think you or anyone else may have taken too many ZIAGEN tablets, immediately telephone your doctor or Poisons Information Centre In Australia telephone 13 11 26.

Otherwise, your doctor may think that it was not effective and change your treatment unnecessarily. If you have forgotten to take a dose of your medicine and it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise, take it as soon as you remember then go back to taking it as you would normally. If you have stopped taking ZIAGEN for any reason, it is important that you contact your doctor before restarting.

This is especially so if you think you are having side-effects or have another illness.

Common Ziagen ide effects may include:

  • Drug interactions Always consult your doctor and pharmacist about taking any other prescription or non-prescription medication, including herbs, supplements, and street drugs.

  • Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in Western Australian HIV Cohort Study.

  • Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

  • Want to avoid this message.

HSRs have been observed with abacavir, some of which have been life-threatening, and in rare cases fatal, when not managed appropriately. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele. Symptoms usually appeared within the first six weeks median time to onset 11 days of initiation of treatment with abacavir, although these reactions may occur at any time during therapy.

Other signs and symptoms that have been observed as part of abacavir HSR are described in detail in section 4. Importantly, such symptoms may lead to misdiagnosis of HSR as respiratory disease pneumonia, bronchitis, pharyngitisor gastroenteritis.

Where can I get more information?

  • Die Wirkungsweise dieser Substanzen besteht in der Hemmung eines viruseigenen Enzyms, der Reversen Transkriptase.

  • You can leave feedback on specific Risk Minimisation Materials or make general observations about how they are displayed on the eMC by leaving comments in the box below.